The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease

Pharmacol Res. 2020 Feb:152:104617. doi: 10.1016/j.phrs.2019.104617. Epub 2019 Dec 24.

Abstract

Increased interest in understanding the liver-kidney axis in health and disease during the last decade unveiled multiple recent evidence that suggested a strong association of fatty liver diseases with chronic kidney disease (CKD). Low-grade systemic inflammation is thought to be the major contributing factor to the pathogenesis of CKD associated with fatty liver. However, other contributing factors largely remained unclear, for example, gut microbiota and intestinal barrier integrity. Homeostasis of the gut microbiome is very crucial for the health of an individual. Imbalance in the gut microbiota leads to various diseases like fatty liver disease and CKD. On the contrary, disease conditions can also distinctly change gut microbiota. In this review, we propose the pathogenic role of the gut-liver-kidney axis in the development and progression of CKD associated with chronic fatty liver diseases, either non-alcoholic fatty liver disease or non-alcoholic steatohepatitis in experimental models and humans. Further, we discuss the therapeutic potential and highlight the future research directions for therapeutic targeting of the gut-liver-kidney axis.

Keywords: CKD; Fibrosis; Gut microbiota; Gut-kidney axis; Gut-liver axis; Inflammation; Insulin resistance; Intestinal barrier integrity; Liver-kidney axis; NAFLD; NASH.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Fatty Liver / complications*
  • Fatty Liver / microbiology
  • Gastrointestinal Microbiome*
  • Humans
  • Intestines*
  • Kidney*
  • Liver*
  • Renal Insufficiency, Chronic / etiology*
  • Renal Insufficiency, Chronic / microbiology